"The program in Comparative Effectiveness and Outcomes Research at Duke University conducts multiple systematic reviews and meta‐analyses each year for professional organizations as well as under both federal and industry sponsored research initiatives. While we use various programs tailored for specific individual projects including those developed in‐house, we have found Comprehensive Meta‐Analysis (CMA) to be a very facile, adaptable and yet comprehensive package meeting the needs for much of our research and generating publication‐quality graphics. My confidence in the analytic algorithms is buoyed by my knowledge of several of the developers of CMA and based on extensive comparison of results with other algorithms including our own. CMA is also an exceptional educational tool and universally embraced by trainees and young investigators initiating careers in evidence‐based medicine and statistical analysis."

Gary H Lyman, MD, MPH, FRCP (Edin) - Professor of Medicine and Director, Comparative Effectiveness and Outcomes Research, Duke University School of Medicine, and the Duke Comprehensive Cancer Center, Senior Fellow, Duke Center for Clinical Health Policy Research, Durham, NC

"The meta‐analysis program is easy to use and provides me with information that would be hard to get by any other means. I analyze a lot of data and, believe it or not, use the meta‐analysis program every day. I am not a statistician, but the results I produce have routinely been verified by statistical consultants costing large amounts for their confirmatory analyses. Without verification, I have used the results to make important decisions regarding a potential billion dollar a year product. At night I wonder, “What would I have done without this great program.”"

Louis Fabre MD, PhD - Chairman, Fabre‐Kramer Pharmaceuticals Inc.